Jun2015
Ariana® Pharma teams together with SIB Swiss Institute of Bioinformatics to discover novel biomarkers for gastric cancer
Leader in clinical big data analytics collaborates with world-class bioinformatics provider in GastricGlycoExplorer consortiumPartnership to develop early detection tools for one of the deadliest cancers Links: Download English PDF | Download French PDF Paris, France, Cambridge, Massachusetts USA, and Geneva, Switzerland, 1 June 2015 – Ariana Pharma, developer of innovative clinical data analysis and diagnostic […]
Jan2015
Nabsys and Ariana Pharma Collaborate to Identify DNA Structural Variants Linked to Targeted Cancers
Nabsys will collaborate with Ariana Pharmaceuticals to identify structural variations related to breast and prostate cancer and how they affect clinical outcome of patients. Links: Download English PDF Providence, Rhode Island, USA, and Paris, FRANCE – January 12th , 2015 – Nabsys, Inc., a life sciences company pioneering semiconductor-based tools for human genomic analysis in […]
Dec2014
Onco KEM(R) platform for personalized cancer treatment selection
Ariana Pharma releases a video to illustrate its innovative Onco KEM® platform for personalized cancer treatment selection. Onco KEM® intends to accelerate the translation of personalized medicine discoveries into widely available new standards of care for all cancer patients, leading to significantly improved clinical outcomes and a higher quality of life for cancer patients. […]
Dec2014
Colloque scientifique annuel du Technion (Paris | December 15)
Dr Mohammad Afshar (Founder and CEO) is joining a prestigious panel of industry leaders to discuss the strategy of open data, data intelligence and data management. Genevieve Fioraso, France’s Deputy Minister for Higher Education & Research and Axelle Lemaire, Deputy Minister in charge of digital tech will participate in the session. Making Sense of BIG […]
Dec2014
GEN corporate profile: Ariana’s Analytics Aim at Predictive Power
Specialist Company Strives to Improve Patient Selection and Treatment Outcomes. Ariana Pharma exhaustively mines and analyzes multiparametric data (biochemical, genomic, proteomic, genetic, metabolic, imaging, clinical, etc.) to identify patient responders and reduce clinical and drug development risks. The process generates actionable information using fewer biomarker signatures than traditional data-mining methods, improving both efficiency and efficacy. […]
Oct2014
Ariana Pharma joins the WIN Consortium as official technology partner
Leader in clinical big data analytics collaborates with global stakeholders in personalized cancer medicine. Partnership to accelerate translation of personalized medicine discoveries into widely available new standards of care for all cancer patients. Links: Download English PDF | Download French PDF Paris, France, and Cambridge, Massachusetts USA, 29 October 2014 – Ariana Pharma, developer of […]
Jul2014
EACR-23: Shorter multimarker signatures: a new tool to facilitate cancer diagnosis
KEM® Biomarker case study presented at EACR-23 this week showed that prognostic signatures generated by KEM® Biomarker have better or similar performances to other classification methods in terms of sensitivity and specificity while having significantly lower number of features in the models. 23rd Biennial Congress of the European Association for Cancer Research. From Basic Research […]
Jul2014
Presentations from WIN 2014 Symposium (Paris | June 23 – 24)
Young researchers from Ariana Pharma presented two posters at the recent WIN 2014 Symposium on breakthrough biomarker investigations and combined therapeutic approaches for precision cancer medicine, held in Paris on 23-24 June 2014. “P2.26: Computational biomarker models to predict response to lung cancer treatments from combined molecular data”, Marine Le Morvan, Maria del Pilar Schneider, […]
Feb2014
Les Echos Innovateurs: Bio-informatique : la FDA choisit le français Ariana Pharma
Une start-up française qui apporte un support technique à la Food and Drug Administration (FDA), c’est tout à fait dérogatoire. C’est pourtant le cas d’ Ariana Pharma, une petite société française spécialisée dans les applications pharmaceutiques du « data mining ». Links: Read online
Feb2014
Effective Design of Multi-Marker Diagnostic Tests for Personalized Medicine
Ariana Pharma releases a video to illustrate the use of its KEM® data mining technology in the effective design of multi-marker diagnostic tests for personalized medicine; KEM® identifies the shortest and most accurate signatures. The video is available on our Vimeo and YouTube channels or can be viewed below. One size doesn’t fit all! […]